Viatris Inc (VTRS)

$16.07 +0.12 (0.75%)
Market Cap 18.37B
Revenue (ttm) 14.74B
Net Income (ttm) -634.20M
EPS (ttm) N/A
PE Ratio 6.83
Forward PE 6.37
Profit Margin -4.30%
Debt to Equity Ratio 1.07
Volume 14,806,699
Avg Vol 9,351,292
Day's Range N/A - N/A
Shares Out 1.15B
Stochastic %K 57%
Beta 0.79
Analysts Sell
Price Target $14.33

Company Profile

Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 724 514 1800
Address:
Robert J. Coury Global Center, 1000 Mylan Boulevard, Canonsburg, United States
ShirleyG
ShirleyG Feb. 25 at 2:55 AM
$VTRS $18 looks good right now🚀🤑
0 · Reply
ZacksResearch
ZacksResearch Feb. 23 at 2:11 PM
$VTRS Q4 earnings preview: Will it overcome challenges? 🤔 Viatris has soared 39.7% over the past year, outpacing its industry, but faces challenges from FDA import alerts affecting Developed Markets. The Zacks Consensus Estimate pins Q4 earnings at $0.52/share on $3.52B revenues. Opportunity assessment here 👉 https://www.zacks.com/stock/news/2873357/viatris-stock-to-report-q4-earnings-whats-in-the-cards?cid=sm-stocktwits-2-2873357-body-34556&ADID=SYND_STOCKTWITS_TWEET_2_2873357_BODY_34556
0 · Reply
ZacksResearch
ZacksResearch Feb. 23 at 1:39 PM
5 medical names heading into earnings — ready for upside surprises or bracing for volatility? $IRWD $RXRX $NVAX $VTRS $NTLA are gearing up to report as the Medical sector shows solid sales growth so far, even with a slight profit dip. That combo can set the stage for sharp moves if expectations get reset. Big reactions could be coming. See what’s at stake for these stocks 👉 https://www.zacks.com/stock/news/2873363/whats-in-store-for-these-5-medical-companies-this-earnings-season?cid=sm-stocktwits-2-2873363-teaser-34570&ADID=SYND_STOCKTWITS_TWEET_2_2873363_TEASER_34570
1 · Reply
ZacksResearch
ZacksResearch Feb. 23 at 1:11 PM
$VTRS up 39.7% in a year — but will Q4 keep the momentum alive? The company heads into earnings facing an Indore import alert and segment revenue pressure, even as margins remain steady. After that kind of run, execution matters more than ever. ⚖️ https://www.zacks.com/stock/news/2873357/viatris-stock-to-report-q4-earnings-whats-in-the-cards?cid=sm-stocktwits-2-2873357-teaser-34554&ADID=SYND_STOCKTWITS_TWEET_2_2873357_TEASER_34554
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 22 at 11:20 PM
$VTRS Current Stock Price: $15.91 Contracts to trade: $16.0 VTRS Mar 20 2026 Call Entry: $0.40 Exit: $0.58 ROI: 44% Hold ~25 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
ShirleyG
ShirleyG Feb. 14 at 7:00 AM
$VTRS whait, what?!!!!🔥🔥🔥 $16 Or why not $18 ⚡️⚡️⚡️⚡️⚡️⚡️⚡️⚡️⚡️⚡️
0 · Reply
Tiger65
Tiger65 Feb. 13 at 6:38 PM
$VTRS the share price has done nothing than go up since the lows of April it has almost doubled. The stock is extremely overbought right now and will at least need to take a breather until the earnings. I built up a security, hedge, I don’t want to sell my $12 LEAPS.
0 · Reply
StockMarketMoodToday
StockMarketMoodToday Feb. 12 at 7:32 PM
$VTRS sold our position in the stock market mood portfolio
0 · Reply
Bwanie
Bwanie Feb. 12 at 5:47 PM
$VTRS I finally jump in and automatically goes down….sorry
0 · Reply
Tiger65
Tiger65 Feb. 11 at 3:59 PM
$WU $PFE $VTRS Little reminder: If you are bullish on a stock and want to help it go up better buy ITM options. The broker has to buy the underlying to hedge its position.
0 · Reply
Latest News on VTRS
FDA Accepts Viatris Supplemental New Drug Application for MR-141 (Phentolamine Ophthalmic Solution 0.75%) for the Treatment of Presbyopia

Feb 25, 2026, 6:59 AM EST - 3 hours ago

FDA Accepts Viatris Supplemental New Drug Application for MR-141 (Phentolamine Ophthalmic Solution 0.75%) for the Treatment of Presbyopia

Viatris: Deep-Value Pharma With Emerging Growth Catalysts And Strong Cash Generation

Feb 20, 2026, 8:52 AM EST - 5 days ago

Viatris: Deep-Value Pharma With Emerging Growth Catalysts And Strong Cash Generation

Mapi Pharma to Host Virtual KOL Event to Discuss Glatiramer Acetate Once a Month Depot for Primary Progressive Multiple Sclerosis, on March 3, 2026

Feb 19, 2026, 9:02 AM EST - 6 days ago

Mapi Pharma to Host Virtual KOL Event to Discuss Glatiramer Acetate Once a Month Depot for Primary Progressive Multiple Sclerosis, on March 3, 2026

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields

Feb 17, 2026, 7:46 AM EST - 8 days ago

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields

CVS UNH

Dividend Income: Lanny's December 2025 Summary

Feb 17, 2026, 6:23 AM EST - 8 days ago

Dividend Income: Lanny's December 2025 Summary

ADM AFL EMR GWW IBM JNJ LYB

Viatris to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026, and Host Investor Event on March 19, 2026

Feb 3, 2026, 4:34 PM EST - 21 days ago

Viatris to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026, and Host Investor Event on March 19, 2026

Viatris Appoints Matthew J. Maletta as Chief Legal Officer

Feb 3, 2026, 8:30 AM EST - 22 days ago

Viatris Appoints Matthew J. Maletta as Chief Legal Officer

Viatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company's First Launch of Inpefa® (Sotagliflozin) for the Treatment of Heart Failure

Jan 20, 2026, 6:59 AM EST - 5 weeks ago

Viatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company's First Launch of Inpefa® (Sotagliflozin) for the Treatment of Heart Failure

LXRX

Viatris Inc. (VTRS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 13, 2026, 4:46 PM EST - 6 weeks ago

Viatris Inc. (VTRS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Viatris Appoints Lara Ramsburg as Chief People and Corporate Affairs Officer

Jan 8, 2026, 9:05 AM EST - 6 weeks ago

Viatris Appoints Lara Ramsburg as Chief People and Corporate Affairs Officer

Mapi Pharma is Seeking New Partnerships for Long-Acting Depot Drugs of Peptides for Self Administration

Jan 6, 2026, 9:00 AM EST - 7 weeks ago

Mapi Pharma is Seeking New Partnerships for Long-Acting Depot Drugs of Peptides for Self Administration

Viatris Provides Pipeline Update on Four Regulatory Milestones

Dec 18, 2025, 6:59 AM EST - 2 months ago

Viatris Provides Pipeline Update on Four Regulatory Milestones

Viatris to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 17, 2025, 6:59 AM EST - 2 months ago

Viatris to Present at the 44th Annual J.P. Morgan Healthcare Conference

Viatris Announces Agreement to Monetize its Equity Stake in Biocon Biologics Limited

Dec 6, 2025, 9:00 AM EST - 2 months ago

Viatris Announces Agreement to Monetize its Equity Stake in Biocon Biologics Limited

Viatris Inc. (VTRS) Presents at Evercore 8th Annual Healthcare Conference Transcript

Dec 3, 2025, 11:13 AM EST - 2 months ago

Viatris Inc. (VTRS) Presents at Evercore 8th Annual Healthcare Conference Transcript

Viatris Inc. (VTRS) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Dec 2, 2025, 11:03 AM EST - 3 months ago

Viatris Inc. (VTRS) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Viatris to Participate in Upcoming Investor Conferences

Nov 24, 2025, 8:00 AM EST - 3 months ago

Viatris to Participate in Upcoming Investor Conferences

Viatris Inc. (VTRS) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 18, 2025, 8:38 AM EST - 3 months ago

Viatris Inc. (VTRS) Presents at Jefferies London Healthcare Conference 2025 Transcript

Viatris Recognized as One of the Fortune World's Best Workplaces™ in 2025

Nov 13, 2025, 8:00 AM EST - 3 months ago

Viatris Recognized as One of the Fortune World's Best Workplaces™ in 2025

Viatris Inc. (VTRS) Presents at UBS Global Healthcare Conference 2025 Transcript

Nov 11, 2025, 12:01 PM EST - 3 months ago

Viatris Inc. (VTRS) Presents at UBS Global Healthcare Conference 2025 Transcript

Viatris Inc. (VTRS) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 2:46 PM EST - 3 months ago

Viatris Inc. (VTRS) Q3 2025 Earnings Call Transcript

Viagra-maker Viatris beats quarterly estimates on strong demand for branded drugs

Nov 6, 2025, 8:16 AM EST - 3 months ago

Viagra-maker Viatris beats quarterly estimates on strong demand for branded drugs

Viatris Reports Third Quarter 2025 Results and Updates 2025 Financial Guidance

Nov 6, 2025, 6:59 AM EST - 3 months ago

Viatris Reports Third Quarter 2025 Results and Updates 2025 Financial Guidance

Viatris Announces Quarterly Dividend

Nov 4, 2025, 6:59 AM EST - 4 months ago

Viatris Announces Quarterly Dividend

Teva Vs. Viatris: Who Will Dominate In President Trump's America?

Oct 17, 2025, 12:18 PM EDT - 4 months ago

Teva Vs. Viatris: Who Will Dominate In President Trump's America?

TEVA

Viatris Completes Acquisition of Aculys Pharma Including Exclusive Rights to Pitolisant in Japan and to Spydia® in Japan and Certain Other Markets in the Asia-Pacific Region

Oct 15, 2025, 4:30 PM EDT - 4 months ago

Viatris Completes Acquisition of Aculys Pharma Including Exclusive Rights to Pitolisant in Japan and to Spydia® in Japan and Certain Other Markets in the Asia-Pacific Region

Buy Any Of 14 IDEAL 'Safer' S&P 500 October Dividend Dogs

Oct 12, 2025, 10:11 AM EDT - 4 months ago

Buy Any Of 14 IDEAL 'Safer' S&P 500 October Dividend Dogs

AES AMCR ARE BMY CAG CPB DOC

Viatris Named to Forbes' Annual List of the World's Best Employers for the Fifth Year in a Row

Oct 8, 2025, 11:00 AM EDT - 5 months ago

Viatris Named to Forbes' Annual List of the World's Best Employers for the Fifth Year in a Row

Viatris to Report Third Quarter 2025 Financial Results on November 6, 2025

Oct 1, 2025, 9:00 AM EDT - 5 months ago

Viatris to Report Third Quarter 2025 Financial Results on November 6, 2025

Viatris: Indore Plant Could Boost 2026 Numbers

Sep 25, 2025, 1:16 PM EDT - 5 months ago

Viatris: Indore Plant Could Boost 2026 Numbers

Viatris Appoints Andrew Enrietti as Chief Administrative and Transformation Officer

Aug 19, 2025, 9:00 AM EDT - 6 months ago

Viatris Appoints Andrew Enrietti as Chief Administrative and Transformation Officer

Dogs Of The S&P 500: Buy 19 Ideal "Safer" August Dividend Payers

Aug 15, 2025, 1:34 PM EDT - 6 months ago

Dogs Of The S&P 500: Buy 19 Ideal "Safer" August Dividend Payers

AMCR ARE BMY BXP CAG CPB CVX

Viatris Announces Approval of First Generic Iron Sucrose Injection in the U.S.

Aug 11, 2025, 9:29 AM EDT - 7 months ago

Viatris Announces Approval of First Generic Iron Sucrose Injection in the U.S.

Viatris Inc. (VTRS) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 11:02 AM EDT - 7 months ago

Viatris Inc. (VTRS) Q2 2025 Earnings Call Transcript

Xanax-maker Viatris beats quarterly profit, revenue estimates; shares rise

Aug 7, 2025, 9:36 AM EDT - 7 months ago

Xanax-maker Viatris beats quarterly profit, revenue estimates; shares rise

Viatris Reports Second Quarter 2025 Results and Reiterates 2025 Financial Guidance

Aug 7, 2025, 6:59 AM EDT - 7 months ago

Viatris Reports Second Quarter 2025 Results and Reiterates 2025 Financial Guidance

Viatris Announces Appointment of David Simmons to the Company's Board of Directors

Aug 5, 2025, 6:55 AM EDT - 7 months ago

Viatris Announces Appointment of David Simmons to the Company's Board of Directors

Viatris Announces Five Data Presentations on Novel Fast-Acting Meloxicam (MR-107A-02) at PAINWeek 2025 Conference

Aug 1, 2025, 10:00 AM EDT - 7 months ago

Viatris Announces Five Data Presentations on Novel Fast-Acting Meloxicam (MR-107A-02) at PAINWeek 2025 Conference

10 dividend stocks with yields up to 6.92% and plenty of cash flow for higher payouts

Jul 22, 2025, 11:19 AM EDT - 7 months ago

10 dividend stocks with yields up to 6.92% and plenty of cash flow for higher payouts

CIVI CMCSA CRGY CWEN KSS LNC NXST

Viatris Hits Snag In Eye Drug Study—Phase 3 Plans Under Review

Jul 18, 2025, 2:17 PM EDT - 7 months ago

Viatris Hits Snag In Eye Drug Study—Phase 3 Plans Under Review

Viatris Stock Tumbles as Eyelid Inflammation Treatment Misses Target

Jul 18, 2025, 8:47 AM EDT - 7 months ago

Viatris Stock Tumbles as Eyelid Inflammation Treatment Misses Target

Viatris eye therapy fails to meet late-stage trial goal

Jul 18, 2025, 7:07 AM EDT - 7 months ago

Viatris eye therapy fails to meet late-stage trial goal

Viatris Provides Update on Phase 3 Study of MR-139 for Blepharitis

Jul 18, 2025, 6:59 AM EDT - 7 months ago

Viatris Provides Update on Phase 3 Study of MR-139 for Blepharitis

Viatris: A Contrarian Bet With Virtually No Downside

Jul 16, 2025, 3:19 AM EDT - 8 months ago

Viatris: A Contrarian Bet With Virtually No Downside

Dogs Of The S&P 500: 14 Ideal 'Safer' July Dividend Buys

Jul 11, 2025, 5:23 PM EDT - 8 months ago

Dogs Of The S&P 500: 14 Ideal 'Safer' July Dividend Buys

AES AMCR ARE BMY CAG CPB CVX

Viatris Announces Positive Top-Line Results from Second Pivotal Phase 3 VEGA-3 Trial of MR-141 in Presbyopia

Jun 26, 2025, 6:55 AM EDT - 8 months ago

Viatris Announces Positive Top-Line Results from Second Pivotal Phase 3 VEGA-3 Trial of MR-141 in Presbyopia

Viatris to Report Second Quarter 2025 Financial Results on August 7, 2025

Jun 12, 2025, 4:30 PM EDT - 9 months ago

Viatris to Report Second Quarter 2025 Financial Results on August 7, 2025

Viatris Inc. (VTRS) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript

Jun 9, 2025, 1:06 PM EDT - 9 months ago

Viatris Inc. (VTRS) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript

Viatris Inc. (VTRS) Presents at Jefferies Global Healthcare Conference Transcript

Jun 5, 2025, 11:04 AM EDT - 9 months ago

Viatris Inc. (VTRS) Presents at Jefferies Global Healthcare Conference Transcript

ShirleyG
ShirleyG Feb. 25 at 2:55 AM
$VTRS $18 looks good right now🚀🤑
0 · Reply
ZacksResearch
ZacksResearch Feb. 23 at 2:11 PM
$VTRS Q4 earnings preview: Will it overcome challenges? 🤔 Viatris has soared 39.7% over the past year, outpacing its industry, but faces challenges from FDA import alerts affecting Developed Markets. The Zacks Consensus Estimate pins Q4 earnings at $0.52/share on $3.52B revenues. Opportunity assessment here 👉 https://www.zacks.com/stock/news/2873357/viatris-stock-to-report-q4-earnings-whats-in-the-cards?cid=sm-stocktwits-2-2873357-body-34556&ADID=SYND_STOCKTWITS_TWEET_2_2873357_BODY_34556
0 · Reply
ZacksResearch
ZacksResearch Feb. 23 at 1:39 PM
5 medical names heading into earnings — ready for upside surprises or bracing for volatility? $IRWD $RXRX $NVAX $VTRS $NTLA are gearing up to report as the Medical sector shows solid sales growth so far, even with a slight profit dip. That combo can set the stage for sharp moves if expectations get reset. Big reactions could be coming. See what’s at stake for these stocks 👉 https://www.zacks.com/stock/news/2873363/whats-in-store-for-these-5-medical-companies-this-earnings-season?cid=sm-stocktwits-2-2873363-teaser-34570&ADID=SYND_STOCKTWITS_TWEET_2_2873363_TEASER_34570
1 · Reply
ZacksResearch
ZacksResearch Feb. 23 at 1:11 PM
$VTRS up 39.7% in a year — but will Q4 keep the momentum alive? The company heads into earnings facing an Indore import alert and segment revenue pressure, even as margins remain steady. After that kind of run, execution matters more than ever. ⚖️ https://www.zacks.com/stock/news/2873357/viatris-stock-to-report-q4-earnings-whats-in-the-cards?cid=sm-stocktwits-2-2873357-teaser-34554&ADID=SYND_STOCKTWITS_TWEET_2_2873357_TEASER_34554
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 22 at 11:20 PM
$VTRS Current Stock Price: $15.91 Contracts to trade: $16.0 VTRS Mar 20 2026 Call Entry: $0.40 Exit: $0.58 ROI: 44% Hold ~25 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
ShirleyG
ShirleyG Feb. 14 at 7:00 AM
$VTRS whait, what?!!!!🔥🔥🔥 $16 Or why not $18 ⚡️⚡️⚡️⚡️⚡️⚡️⚡️⚡️⚡️⚡️
0 · Reply
Tiger65
Tiger65 Feb. 13 at 6:38 PM
$VTRS the share price has done nothing than go up since the lows of April it has almost doubled. The stock is extremely overbought right now and will at least need to take a breather until the earnings. I built up a security, hedge, I don’t want to sell my $12 LEAPS.
0 · Reply
StockMarketMoodToday
StockMarketMoodToday Feb. 12 at 7:32 PM
$VTRS sold our position in the stock market mood portfolio
0 · Reply
Bwanie
Bwanie Feb. 12 at 5:47 PM
$VTRS I finally jump in and automatically goes down….sorry
0 · Reply
Tiger65
Tiger65 Feb. 11 at 3:59 PM
$WU $PFE $VTRS Little reminder: If you are bullish on a stock and want to help it go up better buy ITM options. The broker has to buy the underlying to hedge its position.
0 · Reply
DunkJujus
DunkJujus Feb. 10 at 9:24 PM
$VTRS $18 by Friday.!
0 · Reply
HarveyToronto
HarveyToronto Feb. 10 at 6:02 PM
$VTRS one of my biggest positions. Heading to $18 easy.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 10 at 3:18 AM
$VTRS RSI: 91.67, MACD: 0.6419 Vol: 0.74, MA20: 13.43, MA50: 12.42 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
CoulterB
CoulterB Feb. 10 at 3:03 AM
$VTRS let your winners run. $18
0 · Reply
Avocado_smash
Avocado_smash Feb. 10 at 12:34 AM
$VTRS ✅
0 · Reply
BuyHighSellLowGER
BuyHighSellLowGER Feb. 9 at 10:21 PM
$VTRS Wow, 16$ will be hard to crack. Sell order placed. Most likely won‘t do a $GEV and quadruple from there… lol
0 · Reply
FalconTech
FalconTech Feb. 9 at 10:18 PM
$VTRS Can anyone justify the run up here? Estimated earnings and revenues are ok but nothing to write home about. They are improving the balance sheet but a 50% rise in 6 months? What can explain this? Not complaining at all but trying to decide if it is time to trim a little.
2 · Reply
CoulterB
CoulterB Feb. 9 at 7:10 PM
$VTRS big boys are buying.
0 · Reply
g0at
g0at Feb. 9 at 6:33 PM
$VTRS
0 · Reply
Tiger65
Tiger65 Feb. 9 at 5:39 PM
$VTRS just got in with strike 12$ LEAPS JAN28. They can’t keep this down forever. $PFE $WU
0 · Reply
ShirleyG
ShirleyG Feb. 9 at 1:19 AM
$VTRS we're almost there $15⚡️🚀 But but but WAIT!!!!...what about $18 no?!🤑 LFG🔥🔥🔥
0 · Reply
lextrading
lextrading Feb. 7 at 9:28 PM
$HIMS $TEVA $VTRS Still true. This is a generics company.
0 · Reply